By Michele Maatouk
Date: Tuesday 16 May 2023
(Sharecast News) - Horizon Therapeutics tumbled in pre-market trade on Tuesday following a report that its $27.8bn takeover by Amgen will be challenged by federal regulators.
SEP cashes in as US giant Amgen buys cancer drug... | 26-Jan-2011 | The Scotsman |
Amgen Buys a Cancer Drug Maker | 25-Jan-2011 | New York Times |
Tech Ticker | 16-Dec-2010 | BayArea.com |
Amgen drug delayed spread of prostate cancer to ... | 15-Dec-2010 | LA Times |
Business Briefing | 24-Dec-2009 | LA Times |
Currency | US Dollars |
Share Price | $ 298.62 |
Change Today | $ 0.12 |
% Change | 0.04 % |
52 Week High | $324.56 |
52 Week Low | $218.65 |
Volume | 1,713,616 |
Shares Issued | 535.40m |
Market Cap | $159,881m |
RiskGrade | 100 |
Strong Buy | 6 |
Buy | 8 |
Neutral | 13 |
Sell | 1 |
Strong Sell | 1 |
Total | 29 |
Time | Volume / Share Price |
15:59 | 100 @ $298.63 |
15:59 | 104 @ $298.66 |
15:59 | 100 @ $298.54 |
15:59 | 149 @ $298.55 |
15:59 | 134 @ $298.57 |
You are here: research